Featured Publications
The Lymphatic System in Kidney Disease
Baker M, Cantley L. The Lymphatic System in Kidney Disease. Kidney360 2023, 4: e841-e850. PMID: 37019177, PMCID: PMC10371377, DOI: 10.34067/kid.0000000000000120.Peer-Reviewed Original ResearchConceptsKidney diseaseLymphatic systemSetting of AKIKidney allograft rejectionNormal kidney functionImmune response modulationAllograft rejectionLymph nodesInflammatory infiltrateKidney functionImmune cellsTissue edemaNovel therapiesImmune surveillanceNumerous disease statesSystemic circulationFluid removalKidney tissueResident cellsTherapeutic potentialSurveillance cellsAKIDisease statesKidneyResponse modulationMortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy
Baker ML, Yamamoto Y, Perazella MA, Dizman N, Shirali AC, Hafez N, Weinstein J, Simonov M, Testani JM, Kluger HM, Cantley LG, Parikh CR, Wilson FP, Moledina DG. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy. Journal For ImmunoTherapy Of Cancer 2022, 10: e004421. PMID: 35354588, PMCID: PMC8968986, DOI: 10.1136/jitc-2021-004421.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryCreatinineHumansImmune Checkpoint InhibitorsKidneyNephritis, InterstitialConceptsAcute interstitial nephritisAcute kidney injuryImmune checkpoint inhibitor therapyCheckpoint inhibitor therapyICI therapyKidney injuryInhibitor therapyInterstitial nephritisTime-varying Cox proportional hazards modelsHigher peak serum creatinineSevere acute kidney injuryCancer typesCox proportional hazards modelAssociations of biopsyBaseline laboratory valuesObservational cohort studyPeak serum creatinineFavorable treatment responseProportional hazards modelAKI patientsTherapy initiationCohort studySerum creatinineUnivariable analysisImmune activation
2023
Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US
Patidar K, Belcher J, Regner K, St. Hillien S, Simonetto D, Asrani S, Neyra J, Sharma P, Velez J, Wadei H, Nadim M, Chung R, Seethapathy R, Parada X, Ouyang T, Ufere N, Robinson J, Diaz P, Wilechansky R, Przybyszewski E, Smith T, Ali A, Orman E, Schulz P, Siddiqui S, Shabbir R, Liu L, Cama-Olivares A, Flannery A, Baker M, Gunasekaran D, Aswine A, Issa R, Li J, Verma S, Chalmers D, Varghese V, Lam W, Mohamed M, Kovacic R, Gaddy A, Attieh R, Cortes P, Semnani S, Wang L, Khemichian S, Allegretti A, consortium F. Incidence and outcomes of acute kidney injury including hepatorenal syndrome in hospitalized patients with cirrhosis in the US. Journal Of Hepatology 2023, 79: 1408-1417. PMID: 37517455, PMCID: PMC10807505, DOI: 10.1016/j.jhep.2023.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAgedFemaleHepatorenal SyndromeHumansIncidenceLiver CirrhosisMaleMiddle AgedNecrosisRetrospective StudiesConceptsEtiology of AKIHRS-AKISubdistribution hazard ratiosHepatorenal syndromePrerenal AKIKidney injuryHigh morbidityIncidence ratePractice patternsSimilar outcomesHigher AKI stageAcute kidney injuryRetrospective cohort studyAcute tubular necrosisConsecutive adult patientsEtiology of injuryAKI stageAKI definitionLiver transplantAdult patientsCohort studyHazard ratioSevere complicationsTubular necrosisComplete responsePersonalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial
Aklilu A, O’Connor K, Martin M, Yamamoto Y, Coronel-Moreno C, Shvets K, Jones C, Kadhim B, Corona-Villalobos C, Baker M, Tan J, Freeman N, Groener M, Menez S, Brown D, Culli S, Lindsley J, Orias M, Parikh C, Smith A, Sundararajan A, Wilson F. Personalised recommendations for hospitalised patients with Acute Kidney Injury using a Kidney Action Team (KAT-AKI): protocol and early data of a randomised controlled trial. BMJ Open 2023, 13: e071968. PMID: 37068906, PMCID: PMC10111926, DOI: 10.1136/bmjopen-2023-071968.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryCOVID-19HumansKidneyMulticenter Studies as TopicRandomized Controlled Trials as TopicRenal DialysisSARS-CoV-2ConceptsPrimary teamAcute Kidney Injury OutcomesAKI alert systemInvestigator-blinded trialUsual care armKey secondary outcomesClinical decision support toolIntensive care unitUS hospital systemAKI alertsAKI detectionAKI progressionCare armSecondary outcomesPrimary outcomeCare unitMedian timeMedical floorPercentage of recommendationsDiagnostic interventionsInjury outcomesRandomisationHospital systemEthics CommitteeDedicated team
2020
SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern? Journal Of Nephrology 2020, 33: 985-994. PMID: 32067179, DOI: 10.1007/s40620-020-00712-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAcute Kidney InjuryDiabetes Mellitus, Type 2HumansPharmaceutical PreparationsSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsConceptsType 2 diabetes mellitusAcute kidney injuryChronic kidney diseaseDiabetes mellitusKidney diseaseKidney injuryAlbuminuric chronic kidney diseaseEnd-stage kidney diseaseInhibitor drugsSGLT2 inhibitor therapySignificant cardiovascular benefitsHeart failure hospitalizationGlomerular filtration rateAtherosclerotic cardiovascular diseaseLarge clinical trialsFDA adverse eventsBeneficial cardiovascularKidney benefitsSGLT2 transporterCardiovascular deathFailure hospitalizationAdverse eventsCardiovascular benefitsKidney protectionBlood pressure